← Back to Clinical Trials
Recruiting Phase 4 NCT06991972

NCT06991972 Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06991972
Status Recruiting
Phase Phase 4
Sponsor Khyber Teaching Hospital
Condition Vitiligo
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2025-03-01
Primary Completion 2025-08-31

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Needling + NBUVBMicroneedling + NBUVB

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 80 participants in total. It began in 2025-03-01 with a primary completion date of 2025-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled trial aims to compare the efficacy of needling versus microneedling, both followed by narrowband UVB therapy, in achieving repigmentation in patients with localized stable non-segmental vitiligo.

Eligibility Criteria

Inclusion Criteria: * Both male and female * Age 15-60 years * Patients having vitiligo for more than 1 year Exclusion Criteria: * Patients with tendency of keloid formation or hypertrophic scarring * Patients with any bleeding disorder, coagulation defect or using anti platelets * Any local infection at the treatment site * Patients who had received systemic therapy in last 6 months

Contact & Investigator

Central Contact

Huma Gul Doctor, MBBS

✉ xaffar965@gmail.com

📞 +923471927046

Principal Investigator

Huma Gul Doctor, MBBS

PRINCIPAL INVESTIGATOR

Khyber Teaching Hospital

Frequently Asked Questions

Who can join the NCT06991972 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 60 Years, studying Vitiligo. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06991972 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT06991972 currently recruiting?

Yes, NCT06991972 is actively recruiting participants. Contact the research team at xaffar965@gmail.com for enrollment information.

Where is the NCT06991972 trial being conducted?

This trial is being conducted at Peshawar, Pakistan.

Who is sponsoring the NCT06991972 clinical trial?

NCT06991972 is sponsored by Khyber Teaching Hospital. The principal investigator is Huma Gul Doctor, MBBS at Khyber Teaching Hospital. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology